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Author Contributions: Dr. E. Jenny Heathcote and P. Marcellin had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data. All authors participated in the critical revision of the manuscript for important intellectual content. Results: At week 144, 87% of HBeAg− and 72% of HBeAg+ patients treated with TDF had levels of HBV DNA <400 copies/mL. Among patients who had previously received ADV and then received TDF, 88% of the HBeAg− and 71% of the HBeAg+ patients had levels of HBV DNA <400 copies/mL; overall, 81% and 74%, respectively, maintained normalized levels of ALT and 34% had lost HBeAg. Amino acid substitutions in HBV DNA polymerase that are associated with resistance to tenofovir were not detected in any patient. Cumulatively, 8% of HBeAg+ patients lost HBsAg. TDF maintained a favorable safety profile for up to 3 years. Oral antivirals effectively suppress viral replication; however the development of resistance limits efficacy. Therefore potent antivirals without the propensity to select for resistance are desirable 9 . Safe and well tolerated potent oral antivirals that are able to induce HBsAg loss are increasingly attractive as a therapeutic option since it allows patients to be treated for a finite period of time with safe and well tolerated drugs. Currently, treatment with oral antivirals is response-based whereas treatment with interferon is per a predefined period (per published guidelines for the treatment of CHB). To this point, up to 3 year post treatment efficacy data (including HBsAg loss) has been published in two observational follow-up protocols and observed sustained virological response, defined as either HBV DNA <400 copies/mL or HBV DNA ≤10,000 copies/mL, in 19% and 28% and HBsAg loss in 11% and 8.7% of patients, respectively 10, 11 .
Conclusion
Tenofovir disoproxil fumarate (TDF), the oral prodrug of tenofovir, is a nucleotide analog with potent activity against HBV DNA polymerase and was recently shown to be superior to adefovir dipivoxil (ADV) in HBeAg− and HBeAg+ CHB patients 12 . After 48 weeks of double-blind treatment, HBV DNA was <400 copies/mL in 93% of HBeAg− and 76% HBeAg+ patients on TDF; no resistance mutations developed and notably 3% of HBeAg+ patients also lost HBsAg.
By week 96, 6% of HBeAg+ patients lost HBsAg and no resistance mutations developed 13 .
Studies 102 (HBeAg− patients) and 103 (HBeAg+ patients) were designed to continue assessing the safety and efficacy of TDF treatment through 8 years and although not comparative post week 48, this longer term data may provide some data (albeit limited) into the effect of prolonged viral suppression on clinical outcomes. This manuscript presents results at 3 years of treatment and includes a description of patients initially randomized to ADV after they rolled over to TDF.
METHODS
Study conduct and methods have been previously described 12 AEs, serious AEs (SAEs), laboratory abnormalities, discontinuations due to AEs and deaths were evaluated. Serum phosphorus, serum creatinine and creatinine clearance were evaluated as categorical endpoints (confirmed phosphorus <2 mg/dL, serum creatinine increase from baseline ≥0.5 mg/dL and creatinine clearance <50 mL/min) and creatinine as a continuous variable over time.
RESISTANCE SURVEILLANCE
Changes from pre-TDF treatment in the HBV DNA pol/RT region were assessed annually (and at the time of TDF monotherapy discontinuation and early discontinuation of FTC/TDF) from all patients with persistent viremia and/or virologic breakthrough (confirmed HBV DNA ≥400 copies/mL after being <400 copies/mL or confirmed ≥1 log 10 increase from nadir). Substitutions in the amino acid sequence of the HBV pol/RT domain were evaluated to determine if these substitutions occurred at polymorphic or conserved sites. The population-based di-deoxy sequencing assay required an HBV DNA concentration ≥400 copies/mL (69 IU/mL). All conserved site substitutions were phenotypically assessed in cell culture assays to measure in vitro susceptibility to tenofovir. Phenotyping was also done for polymorphic changes if they were observed in more than 1 patient and for all viruses isolated from patients with virologic breakthrough on study drug. Resistance surveillance testing was conducted by Gilead Sciences (Durham, NC).
STATISTICAL ANALYSES
Efficacy analyses were performed comparing the originally randomized treatment groups, ADV 10 mg and TDF 300 mg. Virologic or HBV DNA response was analyzed using three methods for handling missing data and modifications to the treatment regimen. In the primary analysis,
i.e., long term evaluation (LTE) analysis, using a modified intent-to-treat (ITT) approach, patients discontinuing the study early due to any reason with HBV DNA> 400 copies/mL, or due to death, tolerability, loss to follow-up or had an ongoing AE at the time of discontinuation were all considered failures regardless of HBV DNA suppression. Data considered missing completely at random were excluded from statistical calculations. Patients with HBsAg loss were counted as a success at every visit after HBsAg loss even if their HBV DNA data were missing.
The open-label evaluation analysis (OLE) is a modified ITT (missing=failure) analysis conducted in the population of patients who took at least one dose of open-label TDF. In both the LTE and the OLE analyses, patients who added FTC were considered as treatment failures. The third analysis is an on-treatment analysis which includes all patients on study with non-missing data, regardless of the actual treatment received; all missing data were excluded. Subgroup analyses were performed on the lamivudine and adefovir dipivoxil-experienced patients.
Normalized ALT and HBeAg loss were assessed using an on-treatment method. Analysis of the HBsAg loss was performed using the Kaplan-Meier method. Characteristics of the patients with HBsAg loss are described however due to insufficient numbers of TDF-TDF patients with
HBsAg loss outcome (N=13) no multivariate modeling was conducted. (177/238) of HBeAg+ (75% TDF-TDF; 74% ADV-TDF) patients had HBV DNA <400 copies/mL (69 IU/mL) at week 144. In the on-treatment analysis, 99% HBeAg+ patients had HBV DNA <400 copies/mL at week 144 (in study 103, HBeAg+ patients, 9 were viremic at week 144 with all but one patient having HBV DNA levels <10,000 copies/mL, and 5 discontinued prior to week 144). Of the 17 patients with confirmed viremia beyond week 72 who chose to remain on TDF monotherapy, 12 had HBV DNA <400 copies/mL at week 144, 3 discontinued prior to week 144 and 2 were viremic at week 144 (HBV DNA 437 and 1356 copies/mL).
RESULTS

STUDY POPULATION
Study 102 (HBeAg−
)
SEROLOGICAL RESPONSE and HBsAg QUANTIFICATION RESULTS
In HBeAg+ patients across both treatment groups, HBeAg loss occurred in 34% (34% TDF-TDF, 35% ADV-TDF) and HBeAg seroconversion in 26% of patients (on-treatment analysis). In
HBeAg+ patients, the Kaplan Meier probability of losing HBsAg over 3 years was 8% in each treatment group (N=20 total) ( Figure 3a) ; probability of seroconversion to anti-HBs was 6% and 7% in the TDF-TDF and ADV-TDF groups, respectively (N=15 total). Fourteen of twenty patients discontinued treatment following HBsAg loss; follow up data off therapy is available for Table 2 . Patients who achieved HBsAg loss had a high baseline Knodell necroinflammatory score and higher HBV DNA and HBsAg levels, were genotype A (60%), D (35%) or F (5%) and all were non-Asian, 65% had bridging fibrosis or cirrhosis and the majority were male. These data are descriptive only and would require a larger sample size to support a robust analysis for predictors of HBsAg loss.
BIOCHEMICAL RESPONSE
At week 144 in study 102, 81% of HBeAg− patients (83% TDF-TDF, 77% ADV-TDF) had normalized ALT and mean ALT was 33 U/L while in study 103, 74% of HBeAg+ patients (73% TDF-TDF, 76% ADV-TDF) on treatment at week 144 had normalized ALT and mean ALT was 39 U/L. Ninety-three percent of the elevated ALT concentrations at week 144 were grade 1 or less (≤ 2.5 x ULN).
RESISTANCE SURVEILLANCE
None of the amino acid substitutions in HBV DNA pol/RT that developed through 3 years of treatment were associated with decreased phenotypic sensitivity to tenofovir in either study 102 or 103. Phenotypic analysis of clinical isolates from patients with conserved site changes in HBV DNA pol/RT are presented in Table 3b . Data on conserved site changes observed during year one of the studies has previously been published 13 .
Three of the 29 patients on TDF who had persistent viremia ≥400 copies/mL harbored distinct conserved site changes (rtR51K; rtV173L+L180M +M204V and rtL101F). Clonal analysis of the HBV DNA pol/RT from the patient with lamivudine-associated mutations revealed the presence of these mutations at a frequency of 6.5% at baseline. Phenotypic analysis of these viruses showed full susceptibility to tenofovir in vitro. Eight patients had virologic breakthrough (7/8 due to non-adherence); in all 8 cases the virus isolated remained phenotypically sensitive to inhibition by tenofovir in vitro (data not shown).
Three of 19 patients initially randomized to ADV who were then treated for 2 additional years with TDF monotherapy had distinct conserved site changes (rtG152E; rtN236T + rtR274Q and rtA307T). The rtN236T mutation was observed as a subpopulation (9.3% of the virus population) prior to initiation of TDF therapy; treatment with TDF resulted in a decline of 3.8 log 10 copies/mL in the rtN236T population and the patient achieved HBV DNA <400 copies/mL on continued TDF monotherapy. The other two viruses with conserved site changes were fully sensitive to tenofovir in vitro.
Of the 34 patients who added FTC, 2 of the12 viremic patients evaluated for resistance had virus with conserved site changes at week 144 (rtL180M± rtA181T±rtM204V and rtR192H) in the absence of virologic breakthrough and neither was associated with resistance to tenofovir. Clonal analysis of the baseline isolate demonstrated that the lamivudine-associated mutations (rtL180M± rtA181T±rtM204V) were present at levels ranging from 3.7 to 7.4% of the total viral population at baseline.
SAFETY
The safety profile observed for up to 3 years of TDF was consistent with the known safety profile of the drug 14 Creatinine and creatinine clearance remained stable over 3 years with a change in creatinine of + 0.02 mg/dL at week 144 (Figure 4a and 4b) . Overall, two patients (originally randomized to ADV) experienced a ≥0.5 mg/dL increase in creatinine. Both remained on study through week 144, after a dose reduction in TDF. Four patients (<1%) experienced a reduction in serum phosphorus <2mg/dL which resolved on continued TDF therapy without intervention.
DISCUSSION
With an overall patient retention rate of 85% across the two studies, these 3 year data show 1) subset of patients with pre-existing ADV and LAM-associated mutations) 15, 16, 17, 18 . The previously described rtA194T amino acid substitution was not observed in these studies 19, 20 .
Continued viral suppression has been correlated to improved clinical response and outcomes 21, 22, 23 . Although these data support a correlation between viral suppression and improved clinical outcomes it is virtually impossible to definitively demonstrate this within the confines of a clinical study. More recently a 25-year longitudinal cohort of untreated patients
showed that in addition to older age, male gender and cirrhosis, the risk of liver related mortality was strongly associated with sustained high viral replication independent of HBeAg status 24 .
Although no HBsAg loss was observed among HBeAg− patients the increasing probability of HBsAg loss among HBeAg+ patients over 3 years is encouraging especially given the significant positive impact HBsAg loss has on outcomes such as cirrhosis, liver failure, HCC and overall mortality 6, 7 . The lack of HBsAg loss in HBeAg− patients may be explained by the characteristics of HBeAg− CHB, which is for the most part characterized by milder, intermittent fluctuations in HBV DNA and ALT without evidence of sustained immune control making HBsAg clearance difficult to achieve with oral agents, though sometimes observed with long term follow-up pegylated interferon treatment 11 .
Quantitative HBsAg levels have been used to understand the kinetics of this marker. In HBeAg− patients treated with pegylated interferon alpha-2a for 48 weeks, early kinetics of HBsAg decline was correlated with subsequent loss of HBsAg off treatment 25, 26, 27 and over 7 years the strongest prognostic variable of HBsAg seroconversion was low pretreatment HBsAg levels 25 . In a prospective study, a 0.5 to 1.0 log decline in HBsAg levels at Weeks 12 and 24 were highly predictive of a sustained response following pegylated interferon alpha 2a treatment 26 The proportion of patients (95% CI) with HBV DNA suppression over time is plotted. HBV DNA suppression was defined as HBV DNA level <400 copies/mL (69 IU/mL). In this modified intent-to-treat analysis (LTE) patients who discontinued for safety and efficacy reasons (including patients who discontinued with HBV DNA >400 copies/mL or an ongoing AE at the time of discontinuation) and patients who added emtricitabine are considered failures after discontinuation or the time of emtricitabine addition. Creatinine was measured at regular intervals throughout the 3 years. Creatinine clearance was calculated using the Cockroft-Gault equation. For both studies combined, the overall mean change (min,max) from baseline at week 144 in serum creatinine was 0.02 mg/dL (-0.70, 0.60). In order to deal with the challenges inherent in appropriate management of missing data in long-term efficacy studies, a pre-specified intent-to-treat algorithm (LTE) was defined to allow for subjects withdrawing from the study for administrative reasons to be removed from the denominator for the calculation of virologic response by study visit. When the probability of an observation being missing does not depend on observed or unobserved measurements, then mathematically the observation is missing completely at random. If data are missing at random, then the analysis of only those subjects with complete data gives valid inferences without bias. As a sensitivity-type analysis the open label evaluation analysis was conducted whereby only patients who entered the open label phase are included in the denominator. Patients with missing HBV DNA data at each visit for any reason are considered failures. Lastly, an on-treatment analysis was conducted whereby only patients with data at that visit are included in the denominator. This latter analysis provides relevant virological response data to the clinician regarding patients who remain on treatment. (19) 34 (14) 68 (29) 78 (33) 7 ( Creatinine was measured at regular intervals throughout the 3 years. Creatinine clearance was calculated using the Cockroft-Gault equation. For both studies combined, the overall mean change (min,max) from baseline at week 144 in serum creatinine was 0.02 mg/dL (-0.70, 0.60).
